Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism

American Journal of Emergency Medicine

Volumn 35, Issue 7, 2017, Pages 1039.e5-1039.e7

  Win, Myint Aung ^a   Thein, Kyaw Zin ^a,b   Qdaisat, Aiham ^a   Yeung, Sai Ching Jim ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Hypocalcemia; Hypoparathyroidism; Ipilimumab; Melanoma; Nivolumab; Thyroiditis

Indexed keywords

CALCIFEDIOL; CALCITRIOL; CALCIUM CARBONATE; CALCIUM ION; ERGOCALCIFEROL; GLUCONATE CALCIUM; IPILIMUMAB; LEVOTHYROXINE; MAGNESIUM SULFATE; NIVOLUMAB; PARATHYROID HORMONE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; VITAMIN D; MONOCLONAL ANTIBODY; VITAMIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABDOMINAL RADIOGRAPHY; AGED; ANXIETY; ARTICLE; ATAXIA; AUTOIMMUNE THYROIDITIS; CANCER IMMUNOTHERAPY; CASE REPORT; ELECTROCARDIOGRAPHY; EMERGENCY WARD; FREE THYROXINE INDEX; GRAVES DISEASE; HEART RIGHT BUNDLE BRANCH BLOCK; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; HYPERCALCIURIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPARATHYROIDISM; HYPOTHYROIDISM; LABORATORY TEST; MALE; METASTATIC MELANOMA; MUSCLE WEAKNESS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARATHYROID FUNCTION; PARATHYROID HORMONE BLOOD LEVEL; PARESTHESIA; PRIORITY JOURNAL; QTC INTERVAL; TACHYCARDIA; THYROTOXICOSIS; URINE SAMPLING; ADVERSE EFFECTS; CHEMICALLY INDUCED; IMMUNOTHERAPY; MELANOMA; PROCEDURES; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; CALCIUM GLUCONATE; ERGOCALCIFEROLS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOCALCEMIA; HYPOPARATHYROIDISM; IMMUNOTHERAPY; MAGNESIUM SULFATE; MALE; MELANOMA; TREATMENT OUTCOME; VITAMINS;

EID: 85016744413     PISSN: 07356757     EISSN: 15328171     Source Type: Journal    
DOI: 10.1016/j.ajem.2017.02.048     Document Type: Article

References (10)

1. Mellman, I., Coukos, G., Dranoff, G., Cancer immunotherapy comes of age. Nature 480:7378 (2011), 480–489.
2. Shoback, D., Clinical practice. Hypoparathyroidism. N Engl J Med 359:4 (2008), 391–403.
3. Cholst, I.N., Steinberg, S.F., Tropper, P.J., Fox, H.E., Segre, G.V., Bilezikian, J.P., The influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects. N Engl J Med 310:19 (1984), 1221–1225.
4. Tong, G.M., Rude, R.K., Magnesium deficiency in critical illness. J Intensive Care Med 20:1 (2005), 3–17.
5. Marx, S.J., Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 343:25 (2000), 1863–1875.
6. Thakker, R.V., Genetics of endocrine and metabolic disorders: parathyroid. Rev Endocr Metab Disord 5:1 (2004), 37–51.
7. Ueda, H., Howson, J.M., Esposito, L., Heward, J., Snook, H., Chamberlain, G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:6939 (2003), 506–511.
8. Prokunina, L., Castillejo-Lopez, C., Oberg, F., Gunnarsson, I., Berg, L., Magnusson, V., et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32:4 (2002), 666–669.
9. Michot, J.M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54 (2016), 139–148 (Oxford, England: 1990).
10. Corsello, S.M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., Torino, F., Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98:4 (2013), 1361–1375.